Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Stereotactic Radiotherapy in Neoadjuvant TNBC
NCT06165900Phase 2Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in triple-negative breast cancer (TNBC), sponsored by Shengjing Hospital of China Medical University. Started Sep 2023; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06165900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06165900.